TORONTO and HOUSTON, Sept. 25,
2017 /PRNewswire/ - Medicenna Therapeutics Corp.
("Medicenna" or the "Company") (TSX: MDNA), a clinical stage
immuno-oncology company, today announced that Dr. John Sampson M.D., Ph.D. MBA, Chair of the
Department of Neurosurgery at Duke
University Medical Centre will present at a Late Breaking
Session during the Congress of Neurological Surgeons (CNS) Annual
Meeting to be held from October 7-11,
2017 in Boston, MA.
The oral presentation by Dr. Sampson will provide an interim
safety and tolerability evaluation of high flow convection enhanced
delivery (CED) of the targeted immunotherapy MDNA55 in an early
cohort of patients from the ongoing Phase 2b clinical study for the
treatment of recurrent glioblastoma, the most common and deadly
form of brain cancer.
The details of the presentation are as follows:
Title:
|
Real time, image
guided high flow CED in recurrent glioblastoma (rGBM); initial
experience from phase II study of a targeted immunotherapy, MDNA55
(cpIL-4PE)
|
Date:
|
Tuesday, October 10,
2017
|
Time:
|
7:48 AM
|
Session:
|
Late Breaking
Abstract Session
|
Session
ID:
|
250 (sub session
250-90)
|
Location:
|
258B – Boston
Convention and Exhibition Center
|
About Medicenna Therapeutics Corp.
Medicenna is a clinical stage immuno-oncology company developing
novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™
and first in class Empowered Cytokines™ (ECs). Its wholly
owned subsidiary, Houston-based Medicenna BioPharma, is
specifically targeting the Interleukin-4 Receptor (IL4R), which is
over-expressed by at least 20 different types of cancer affecting
more than one million new cancer patients every year. Medicenna's
lead IL4-EC, MDNA55 is enrolling patients in a CPRIT (Cancer
Prevention and Research Institute of Texas) funded Phase 2b clinical trial for rGBM
at leading brain cancer centres in the US. MDNA55 has completed 3
clinical trials in 72 patients, including 66 adults with rGBM,
demonstrated compelling efficacy and obtained Fast-Track and Orphan
Drug status from USFDA. Unlike most other cancer therapies,
Medicenna's IL4-ECs have the potential to purge both the tumor and
the immunosuppressive tumor microenvironment, offering a unique
treatment paradigm for a large majority of cancer patients.
For more information, please visit www.medicenna.com.
For further information This news release contains
forward-looking statements relating to the future operations of the
Company and other statements that are not historical facts.
Forward-looking statements are often identified by terms such as
"will", "may", "should", "anticipate", "expects" and similar
expressions. All statements other than statements of historical
fact, included in this release, including, without limitation,
statements regarding future plans and objectives of the Company and
others are forward-looking statements that involve risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and actual results and future events could
differ materially from those anticipated in such statements.
Important factors that could cause actual results to differ
materially from the Company's expectations include the risks
detailed in the annual information form of the Company dated
June 15, 2017 and in other filings
made by the Company with the applicable securities regulators from
time to time.
The reader is cautioned that assumptions used in the
preparation of any forward-looking information may prove to be
incorrect. Events or circumstances may cause actual results to
differ materially from those predicted, as a result of numerous
known and unknown risks, uncertainties, and other factors, many of
which are beyond the control of the Company. The reader is
cautioned not to place undue reliance on any forward-looking
information. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made
as of the date of this news release and the Company will update or
revise publicly any of the included forward-looking statements only
as expressly required by Canadian securities law.
SOURCE Medicenna Therapeutics Corp.